In Brief: Chantal
This article was originally published in The Rose Sheet
Executive Summary
Chantal: Delaying release of 10-K filing for fiscal year 1996 (ended June 30) to the SEC as a result of Coopers & Lybrand's resignation as Chantal Pharmaceutical's independent accounting firm in August, the company announced Nov. 15. Chantal retained BDO Seidman in September ("The Rose Sheet" Sept. 23, In Brief) to complete the audit of the firm's 1996 results. Chantal noted it is in "regular communication" with NASDAQ and "intends to report" its annual results within the time allotted by SEC. Chantal was notified by NASDAQ in May that it risked delisting from the SmallCap stock market due to overdue reporting of its second and third quarter results ("The Rose Sheet" May 27, p. 8)...